Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa

BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson's disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. METHODS: Data were collected from seve...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Parkinsons Dis
Huvudupphovsmän: Zadikoff, Cindy, Poewe, Werner, Boyd, James T., Bergmann, Lars, Ijacu, Horia, Kukreja, Pavnit, Robieson, Weining Z., Benesh, Janet, Antonini, Angelo
Materialtyp: Artigo
Språk:Inglês
Publicerad: Hindawi 2020
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7040420/
https://ncbi.nlm.nih.gov/pubmed/32104560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9716317
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk